Share on StockTwits

Biota Pharmaceuticals (NASDAQ:BOTA) was downgraded by research analysts at TheStreet from a “hold” rating to a “sell” rating in a report released on Friday.

The analysts wrote, “Biota Pharmaceuticals (BOTA) has been downgraded by TheStreet Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its poor profit margins and generally disappointing historical performance in the stock itself.”

Biota Pharmaceuticals (NASDAQ:BOTA) traded down 2.89% during mid-day trading on Friday, hitting $2.69. 104,836 shares of the company’s stock traded hands. Biota Pharmaceuticals has a one year low of $2.68 and a one year high of $7.07. The stock’s 50-day moving average is $3.92 and its 200-day moving average is $4.79. The company’s market cap is $94.4 million.

Biota Pharmaceuticals (NASDAQ:BOTA) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.28) by $0.37. On average, analysts predict that Biota Pharmaceuticals will post $-0.22 earnings per share for the current fiscal year.

Biota Pharmaceuticals, Inc, formerly Nabi Biopharmaceuticals, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.